France
  • /
  • Europe
  • Europa
  • Britain
  • Germany
  • Italy
  • Spain
  • Russia
  • Ukraine
  • Africa
  • Tennis
  • FR
    • Afrique
  • France
    • Roland-Garros
  • …
    • Poland
    • Netherlands
    • Iran
    • Canada
    • Australia
    • Japan
  • @
  • Air France
  • Airbus
  • AXA
  • BNP Paribas
  • Bulgari
  • Carrefour
  • Christian Dior
  • CMA CGM
  • Crédit Agricole
  • Dassault Aviation
  • Dassault Systèmes
  • Électricité de France
  • ENGIE
  • Fendi
  • France
  • Hermès
  • L'Oréal
  • Louis Vuitton
  • LVMH
  • Paris
  • Renault
  • Safran
  • Sanofi
  • Schneider Electric
  • Sephora
  • Société Générale
  • Stellantis
  • Thales
  • Tiffany & Co.
  • TotalEnergies
France
  • /
  • Europe
  • Europa
  • Britain
  • Germany
  • Italy
  • Spain
  • Russia
  • Ukraine
  • Africa
  • Tennis
  • FR
    • Afrique
  • France
    • Roland-Garros
  • …
    • Poland
    • Netherlands
    • Iran
    • Canada
    • Australia
    • Japan
  • @

Browsing Tag

clinical study

8 posts
SSanofi
Press Release: Sanofi Foundation opens new chapter centered on future generations
Read More

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

  • June 29, 2026
Sanofi Winthrop Industrie Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive…
SSanofi
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Read More

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

  • June 23, 2026
Sanofi Winthrop Industrie Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive…
SSanofi
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Read More

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

  • June 13, 2026
Sanofi Winthrop Industrie Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed…
SSanofi
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Read More

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

  • June 12, 2026
Sanofi Winthrop Industrie Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed…
SSanofi
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Read More

Press Release: Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

  • May 31, 2026
Sanofi Winthrop Industrie Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1…
SSanofi
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Read More

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

  • May 22, 2026
Sanofi Winthrop Industrie Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative…
SSanofi
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Read More

Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

  • May 22, 2026
Sanofi Winthrop Industrie AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking…
SSanofi
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Read More

Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

  • May 22, 2026
Sanofi Winthrop Industrie Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple…
France
www.europesays.com